{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:27:18Z","timestamp":1793212038935,"version":"4.5.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s40264-019-00881-8","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T17:03:13Z","timestamp":1572627793000},"page":"147-161","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Exposure to Infliximab During Pregnancy: Post-Marketing Experience"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6476-5526","authenticated-orcid":false,"given":"Anja","family":"Geldhof","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Slater","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urmila","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Coppola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"key":"881_CR1","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1111\/j.1572-0241.1998.00698.x","volume":"93","author":"K Fonager","year":"1998","unstructured":"Fonager K, S\u00f8rensen HT, Olsen J, et al. Pregnancy outcome for women with Crohn\u2019s disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998;93:2426\u201330.","journal-title":"Am J Gastroenterol."},{"key":"881_CR2","first-page":"211","volume":"6","author":"PJ Baiocco","year":"1984","unstructured":"Baiocco PJ, Korelitz BI. The influence of inflammatory bowel disease and its treatment on pregnancy and fetal outcome. J Clin Gastroenterol. 1984;6:211\u20136.","journal-title":"J Clin Gastroenterol."},{"key":"881_CR3","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1136\/ard.2008.105262","volume":"69","author":"HC Lin","year":"2010","unstructured":"Lin HC, Chen SF, Lin HC, et al. Increased risk of adverse pregnancy outcomes in women with rheumatoid arthritis: a nationwide population-based study. Ann Rheum Dis. 2010;69:715\u20137.","journal-title":"Ann Rheum Dis."},{"key":"881_CR4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.14547","volume":"175","author":"R Bobotsis","year":"2016","unstructured":"Bobotsis R, Gulliver WP, Monaghan K, et al. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol. 2016;175:464\u201372.","journal-title":"Br J Dermatol."},{"key":"881_CR5","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1572-0241.2007.01756.x","volume":"103","author":"D Reddy","year":"2008","unstructured":"Reddy D, Murphy SJ, Kane SV, et al. Relapses of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol. 2008;103:1203\u20139.","journal-title":"Am J Gastroenterol."},{"key":"881_CR6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/gut.25.1.52","volume":"25","author":"R Khosla","year":"1984","unstructured":"Khosla R, Willoughby CP, Jewell DP. Crohn\u2019s disease and pregnancy. Gut. 1984;25:52\u20136.","journal-title":"Gut."},{"key":"881_CR7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1136\/gut.27.7.821","volume":"27","author":"JF Mayberry","year":"1986","unstructured":"Mayberry JF, Weterman IT. European survey of fertility and pregnancy in women with Crohn\u2019s disease: a case control study by European Collaborative Group. Gut. 1986;27:821\u20135.","journal-title":"Gut."},{"key":"881_CR8","first-page":"265","volume":"75","author":"M Mogadam","year":"1981","unstructured":"Mogadam M, Korelitz BI, Ahmed SW, et al. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol. 1981;75:265\u20139.","journal-title":"Am J Gastroenterol."},{"issue":"8","key":"881_CR9","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/acr.22000","volume":"65","author":"E Vinet","year":"2013","unstructured":"Vinet E, Kuriya B, Pineau CA, Clarke AE, Bernatsky S. Induced abortions in women with rheumatoid arthritis receiving methotrexate. Arthritis Care Res (Hoboken). 2013;65(8):1365\u20139.","journal-title":"Arthritis Care Res (Hoboken)."},{"key":"881_CR10","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/bcp.12947","volume":"82","author":"JE Given","year":"2016","unstructured":"Given JE, Loane M, Luteijn JM, et al. EUROmediCAT signal detection: an evaluation of selected congenital anomaly-medication associations. Br J Clin Pharmacol. 2016;82:1094\u2013109.","journal-title":"Br J Clin Pharmacol."},{"key":"881_CR11","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1016\/S0264-410X(03)00334-7","volume":"21","author":"NE Simister","year":"2003","unstructured":"Simister NE. Placental transport of immunoglobulin G. Vaccine. 2003;21:3365\u20139.","journal-title":"Vaccine."},{"key":"881_CR12","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/ajg.2011.5","volume":"106","author":"R Arsenescu","year":"2011","unstructured":"Arsenescu R, Arsenescu V, de Villiers WJ. TNF-alpha and the development of the neonatal immune system: implications for inhibitor use in pregnancy. Am J Gastroenterol. 2011;106:559\u201362.","journal-title":"Am J Gastroenterol."},{"key":"881_CR13","unstructured":"The American College of Obstetricians and Gynecologists. Early pregnancy loss: miscarriage and molar pregnancy. Washington, DC. FAQ090, August 2015."},{"key":"881_CR14","first-page":"1","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","unstructured":"Centers for Disease Control and Prevention (CDC). Update on overall prevalence of major birth defects: Atlanta, Georgia, 1978\u20132005. MMWR Morb Mortal Wkly Rep. 2008;57:1\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"881_CR15","unstructured":"Chambers CJ, Johnson DL, Luo Y, et al. Serious or opportunistic infections in infants born to women with rheumatoid arthritis treated with a biologic medication [abstract]. Arthritis Rheum. 2017;69 (Suppl. 10). \nhttps:\/\/acrabstracts.org\/abstract\/serious-or-opportunistic-infections-in-infants-born-to-pregnant-women-with-rheumatoid-arthritis-and-treated-with-a-biologic-medication\/\n\n. Accessed 26 Feb 2019."},{"issue":"2","key":"881_CR16","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/annrheumdis-2016-209322","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Landew\u00e9 R, Genovese MC, et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017;76(2):414\u20137.","journal-title":"Ann Rheum Dis."},{"key":"881_CR17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/pds.4261","volume":"26","author":"WJ Carman","year":"2017","unstructured":"Carman WJ, Accortt NA, Anthony MS, et al. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf. 2017;26:1109\u201318.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"881_CR18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/ajg.2012.430","volume":"108","author":"MJ Casanova","year":"2013","unstructured":"Casanova MJ, Chaparro M, Domenech E, et al. Safety of thiopurines and anti-TNF-\u03b1 drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:433\u201340.","journal-title":"Am J Gastroenterol."},{"key":"881_CR19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/art.38262","volume":"66","author":"WO Cooper","year":"2014","unstructured":"Cooper WO, Cheetham TC, Li DK, et al. Adverse fetal outcomes associated with immunosuppressive medications for chronic immune mediated diseases in pregnancy. Arthritis Rheumatol. 2014;66:444\u201350.","journal-title":"Arthritis Rheumatol."},{"key":"881_CR20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.reprotox.2013.11.004","volume":"43","author":"O Diav-Citrin","year":"2014","unstructured":"Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, et al. Pregnancy outcome following gestational exposure to TNF-\u03b1-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78\u201384.","journal-title":"Reprod Toxicol."},{"key":"881_CR21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5217\/ir.2016.14.2.139","volume":"14","author":"S Komoto","year":"2016","unstructured":"Komoto S, Motoya S, Nishiwaki Y, et al. Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and\/or thiopurine therapy: a multicenter study from Japan. Intest Res. 2016;14:139\u201345.","journal-title":"Intest Res."},{"key":"881_CR22","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1002\/ibd.21583","volume":"17","author":"F Schnitzler","year":"2011","unstructured":"Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846\u201354.","journal-title":"Inflamm Bowel Dis."},{"key":"881_CR23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/apt.12833","volume":"40","author":"M Seirafi","year":"2014","unstructured":"Seirafi M, de Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:363\u201373.","journal-title":"Aliment Pharmacol Ther."},{"key":"881_CR24","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1097\/MIB.0000000000001234","volume":"23","author":"H Kammerlander","year":"2017","unstructured":"Kammerlander H, Nielsen J, Knudsen T, et al. Anti-TNF-\u03b1 use during the third trimester of pregnancy in women with moderate-severe inflammatory bowel disease and the risk of preterm birth and low birth weight. Inflamm Bowel Dis. 2017;23:1916\u201323.","journal-title":"Inflamm Bowel Dis."},{"issue":"234\u201341","key":"881_CR25","first-page":"e1","volume":"14","author":"G Br\u00f6ms","year":"2016","unstructured":"Br\u00f6ms G, Granath F, Ekbom A, et al. Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy. Clin Gastroenterol Hepatol. 2016;14(234\u201341):e1\u20135.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"881_CR26","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/ajg.2017.501","volume":"113","author":"M Chaparro","year":"2018","unstructured":"Chaparro M, Verreth A, Lobaton T, et al. Long-term safety of in utero exposure to anti-TNF alpha drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study. Am J Gastroenterol. 2018;113:396\u2013403.","journal-title":"Am J Gastroenterol."},{"key":"881_CR27","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1038\/s41395-018-0202-9","volume":"113","author":"GR Lichtenstein","year":"2018","unstructured":"Lichtenstein GR, Feagan BG, Mahadevan U, et al. Pregnancy outcomes reported during the 13-year TREAT Registry: a descriptive report. Am J Gastroenterol. 2018;113:1678\u201388.","journal-title":"Am J Gastroenterol."},{"key":"881_CR28","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1002\/art.40536","volume":"70","author":"\u00c9 Vinet","year":"2018","unstructured":"Vinet \u00c9, De Moura C, Pineau CA, et al. Serious infections in rheumatoid arthritis offspring exposed to tumor necrosis factor inhibitors: a cohort study. Arthritis Rheumatol. 2018;70:1565\u201371.","journal-title":"Arthritis Rheumatol."},{"key":"881_CR29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaut.2016.11.004","volume":"76","author":"F Komaki","year":"2017","unstructured":"Komaki F, Komaki Y, Micic D, et al. Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-\u03b1 use in females with immune mediated diseases; a systematic review and meta-analysis. J Autoimmun. 2017;76:38\u201352.","journal-title":"J Autoimmun."},{"key":"881_CR30","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.22374\/1710-6222.25.1.5","volume":"25","author":"K Mirdamadi","year":"2018","unstructured":"Mirdamadi K, Salinas T, Vali R, et al. Meta-analysis of pregnancy outcomes after exposure to TNF-alpha inhibitors for the treatment of arthritic diseases: a meta-analysis of observational studies. J Popul Ther Clin Pharmacol. 2018;25:e53\u20136.","journal-title":"J Popul Ther Clin Pharmacol."},{"key":"881_CR31","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2017-212196","volume":"77","author":"X Mariette","year":"2018","unstructured":"Mariette X, F\u00f6rger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis. 2018;77:228\u201333.","journal-title":"Ann Rheum Dis."},{"key":"881_CR32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/bcpt.12367","volume":"116","author":"AM Bj\u00f8rn","year":"2015","unstructured":"Bj\u00f8rn AM, Ehrenstein V, Nohr EA, et al. Use of inhaled and oral corticosteroids in pregnancy and the risk of malformations or miscarriage. Basic Clin Pharmacol Toxicol. 2015;116:308\u201314.","journal-title":"Basic Clin Pharmacol Toxicol."},{"key":"881_CR33","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3109\/14767058.2013.860523","volume":"27","author":"R Sanya","year":"2014","unstructured":"Sanya R, Al Naggar E, Gasim M, et al. Use or overuse of antenatal corticosteroids for suspected preterm birth. J Matern Fetal Neonatal Med. 2014;27:1454\u20136.","journal-title":"J Matern Fetal Neonatal Med."},{"key":"881_CR34","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z","volume":"62","author":"L Park-Wyllie","year":"2000","unstructured":"Park-Wyllie L, Mazzotta P, Pastuszak A, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62:385\u201392.","journal-title":"Teratology."},{"key":"881_CR35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/bdra.23509","volume":"106","author":"AV Plauborg","year":"2016","unstructured":"Plauborg AV, Hansen AV, Garne E. Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease. Birth Defects Res A Clin Mol Teratol. 2016;106:494\u20139.","journal-title":"Birth Defects Res A Clin Mol Teratol."},{"key":"881_CR36","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1002\/ajmg.a.36625","volume":"164","author":"AL Dawson","year":"2014","unstructured":"Dawson AL, Riehle-Colarusso T, Reefhuis J, Arena JF, National Birth Defects Prevention Study. Maternal exposure to methotrexate and birth defects: a population-based study. Am J Med Genet A. 2014;164:2212\u20136.","journal-title":"Am J Med Genet A"},{"key":"881_CR37","unstructured":"Methotrexate sodium for injection. Florence (KY): Xanodyne Pharmacal, Inc; 2003."},{"key":"881_CR38","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/pds.4410","volume":"27","author":"K Palmsten","year":"2018","unstructured":"Palmsten K, Rolland M, Hebert MF, et al. Patterns of prednisone use during pregnancy in women with rheumatoid arthritis: daily and cumulative dose. Pharmacoepidemiol Drug Saf. 2018;27:430\u20138.","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"881_CR39","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/art.38919","volume":"67","author":"M Wallenius","year":"2015","unstructured":"Wallenius M, Lie E, Daltveit AK, et al. No excess risks in offspring with paternal preconception exposure to disease-modifying antirheumatic drugs. Arthritis Rheumatol. 2015;67:296\u2013301.","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl. 2","key":"881_CR40","first-page":"802","volume":"75","author":"MC Micu","year":"2016","unstructured":"Micu MC, Bojinca V, Mihai M, et al. Pregnancy outcome in couples with males exposed to longterm anti-TNF alpha blocker therapies. Ann Rheum. 2016;75(Suppl. 2):802.","journal-title":"Ann Rheum."},{"issue":"9","key":"881_CR41","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.3899\/jrheum.180588","volume":"46","author":"MC Micu","year":"2019","unstructured":"Micu MC, Ostensen M, Bojinca V, et al. Pregnancy outcomes in couples with males exposed to long term anti-TNF alpha blocker therapies: a prospective study. J Rheumatol. 2019;46(9):1084\u20138. \nhttps:\/\/doi.org\/10.3899\/jrheum.180588\n\n.","journal-title":"J Rheumatol."},{"key":"881_CR42","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.semarthrit.2018.07.011","volume":"48","author":"M Mouyis","year":"2019","unstructured":"Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: a systematic review and analysis of published evidence. Semin Arthritis Rheum. 2019;48:911\u201320.","journal-title":"Semin Arthritis Rheum."},{"key":"881_CR43","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1038\/ajg.2016.405","volume":"111","author":"MD Larsen","year":"2016","unstructured":"Larsen MD, Friedman S, Magnussen B, et al. Birth outcomes in children fathered by men treated with anti-TNF-\u03b1 agents before conception. Am J Gastroenterol. 2016;111:1608\u201313.","journal-title":"Am J Gastroenterol."},{"key":"881_CR44","unstructured":"Pregnancy due date and gestational age calculator. 2016. \nhttp:\/\/www.perinatology.com\/calculators\/Due-Date.htm\n\n. Accessed 21 Sept 2017."},{"key":"881_CR45","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Clinical safety data management: definitions and standards for expedited reporting E2A, 1994."},{"key":"881_CR46","unstructured":"Rules governing medicinal products in the European Union. Guidelines on pharmacovigilance for medicinal products for human use. Volume 9A, 2008."},{"key":"881_CR47","volume-title":"Congenital anomalies: definitions","author":"Centers for Disease Control and Prevention","year":"2018","unstructured":"Centers for Disease Control and Prevention. Congenital anomalies: definitions. US Department of Health & Human Services. Washington, DC, 2018."},{"key":"881_CR48","first-page":"41","volume":"26","author":"J Jones","year":"2017","unstructured":"Jones J, Borgaonkar M, Siffledeen J, et al. Bioadvance patient support program survey: positive perception of intravenous infusions of infliximab. Manag Care. 2017;26:41\u20138.","journal-title":"Manag Care."},{"key":"881_CR49","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00431-017-2864-5","volume":"176","author":"HJR van der Horst","year":"2017","unstructured":"van der Horst HJR, de Wall LL. Hypospadias, all there is to know. Eur J Pediatr. 2017;176:435\u201341.","journal-title":"Eur J Pediatr."},{"key":"881_CR50","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jpeds.2008.05.059","volume":"153","author":"MD Reller","year":"2008","unstructured":"Reller MD, Strickland MJ, Riehle-Colarusso T, et al. Prevalence of congenital heart defects in metropolitan Atlanta, 1998\u20132005. J Pediatr. 2008;153:807\u201313.","journal-title":"J Pediatr."},{"key":"881_CR51","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/bdra.20735","volume":"88","author":"SE Parker","year":"2010","unstructured":"Parker SE, Mai CT, Canfield MA, et al. Updated national birth prevalence estimates for selected birth defects in the United States, 2004\u20132006. Birth Defects Res A Clin Mol Teratol. 2010;88:1008\u201316.","journal-title":"Birth Defects Res A Clin Mol Teratol."},{"key":"881_CR52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2147\/IJWH.S6029","volume":"2","author":"ME Clowse","year":"2010","unstructured":"Clowse ME. The use of anti-TNF\u03b1 medications for rheumatologic disease in pregnancy. Int J Womens Health. 2010;2:199\u2013209.","journal-title":"Int J Womens Health."},{"key":"881_CR53","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3899\/jrheum.080545","volume":"36","author":"JD Carter","year":"2009","unstructured":"Carter JD, Ladhani A, Ricca LR, et al. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009;36:635\u201341.","journal-title":"J Rheumatol."},{"key":"881_CR54","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3899\/jrheum.081083","volume":"36","author":"G Koren","year":"2009","unstructured":"Koren G, Inoue M. Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol. 2009;36:465\u20136.","journal-title":"J Rheumatol."},{"key":"881_CR55","unstructured":"Infliximab periodic benefit risk evaluation report\/periodic safety update report. Horsham (PA): Janssen Research & Development, LLC; 2018."},{"key":"881_CR56","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","volume":"99","author":"JA Katz","year":"2004","unstructured":"Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn\u2019s disease and rheumatoid arthritis. Am J Gastroenterol. 2004;99:2385\u201392.","journal-title":"Am J Gastroenterol."},{"key":"881_CR57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/uog.12442","volume":"42","author":"A Borrell","year":"2013","unstructured":"Borrell A, Stergiotou I. Miscarriage in contemporary maternal-fetal medicine: targeting clinical dilemmas. Ultrasound Obstet Gynecol. 2013;42:491\u20137.","journal-title":"Ultrasound Obstet Gynecol."},{"key":"881_CR58","first-page":"1","volume":"64","author":"BE Hamilton","year":"2015","unstructured":"Hamilton BE, Martin JA, Osterman MJ, et al. Births: final data for 2014. Natl Vital Stat Rep. 2015;64:1\u201364.","journal-title":"Natl Vital Stat Rep."},{"key":"881_CR59","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.semperi.2017.07.004","volume":"41","author":"RS Kirby","year":"2017","unstructured":"Kirby RS. The prevalence of selected major birth defects in the United States. Semin Perinatol. 2017;41:338\u201344.","journal-title":"Semin Perinatol."},{"key":"881_CR60","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/AOG.0b013e31829cbbb4","volume":"122","author":"RS Kirby","year":"2013","unstructured":"Kirby RS, Marshall J, Tanner JP, et al. Prevalence and correlates of gastroschisis in 15 states, 1995 to 2005. Obstet Gynecol. 2013;122:275\u201381.","journal-title":"Obstet Gynecol."},{"key":"881_CR61","doi-asserted-by":"crossref","first-page":"23","DOI":"10.15585\/mmwr.mm6502a2","volume":"65","author":"Centers for Disease Control and Prevention (CDC)","year":"2016","unstructured":"Centers for Disease Control and Prevention (CDC). Increasing prevalence of gastroschisis: 14 states, 1995\u20132012. MMWR Morb Mortal Wkly Rep. 2016;65:23\u20136.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"881_CR62","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1002\/ajmg.a.37883","volume":"170A","author":"AM Padula","year":"2016","unstructured":"Padula AM, Yang W, Schultz K, et al. Gene variants as risk factors for gastrochisis. Am J Med Genet Part A. 2016;170A:2788\u2013802.","journal-title":"Am J Med Genet Part A."},{"key":"881_CR63","unstructured":"Centers for Disease Control and Prevention (CDC). Atrial septal defects. \nhttps:\/\/rarediseases.org\/rare-diseases\/atrial-septal-defects\/\n\n. Accessed 06 Dec 2018."},{"key":"881_CR64","unstructured":"Centers for Disease Control and Prevention (CDC). Occurrence of Down syndrome in the United States. 2017. \nhttps:\/\/www.cdc.gov\/ncbddd\/birthdefects\/downsyndrome\/data.html\n\n. Accessed 06 Dec 2018."},{"key":"881_CR65","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1097\/MIB.0000000000000092","volume":"20","author":"N Narula","year":"2014","unstructured":"Narula N, Al-Dabbagh R, Dhillon A, et al. Anti-TNF\u03b1 therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1862\u20139.","journal-title":"Inflamm Bowel Dis."},{"key":"881_CR66","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/ecco-jcc\/jjv234","volume":"10","author":"Z Shihab","year":"2016","unstructured":"Shihab Z, Yeomans ND, De Cruz P. Anti-tumour necrosis factor \u03b1 therapies and inflammatory bowel disease pregnancy outcomes: a meta-analysis. J Crohns Colitis. 2016;10:979\u201388.","journal-title":"J Crohns Colitis."},{"key":"881_CR67","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1136\/gutjnl-2015-309321","volume":"65","author":"A de Lima","year":"2016","unstructured":"de Lima A, Zelinkova Z, van der Ent C, et al. Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety. Gut. 2016;65:1261\u20138.","journal-title":"Gut."},{"key":"881_CR68","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1111\/bcp.12642","volume":"80","author":"C Weber-Schoendorfer","year":"2015","unstructured":"Weber-Schoendorfer C, Oppermann M, Wacker E, et al. Pregnancy outcome after TNF-\u03b1 inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol. 2015;80:727\u201339.","journal-title":"Br J Clin Pharmacol."},{"key":"881_CR69","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/art.38368","volume":"66","author":"C Weber-Schoendorfer","year":"2014","unstructured":"Weber-Schoendorfer C, Chambers C, Wacker E, et al. Pregnancy outcome after methotrexate treatment for rheumatic disease prior to or during early pregnancy: a prospective multicenter cohort study. Arthritis Rheumatol. 2014;66:1101\u201310.","journal-title":"Arthritis Rheumatol."},{"key":"881_CR70","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.3389\/fimmu.2017.01123","volume":"8","author":"A Esteve-Sol\u00e9","year":"2017","unstructured":"Esteve-Sol\u00e9 A, Deya-Martinez A, Teixido I, et al. Immunological changes in blood of newborns exposed to anti-TNF-\u03b1 during pregnancy. Front Immunol. 2017;8:1123.","journal-title":"Front Immunol."},{"key":"881_CR71","doi-asserted-by":"crossref","first-page":"e1189","DOI":"10.1542\/peds.2014-0054","volume":"134","author":"T Guiddir","year":"2014","unstructured":"Guiddir T, Fr\u00e9mond ML, Triki TB, et al. Anti-TNF-\u03b1 therapy may cause neonatal neutropenia. Pediatrics. 2014;134:e1189\u201393.","journal-title":"Pediatrics."},{"key":"881_CR72","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","volume":"113","author":"M Luu","year":"2018","unstructured":"Luu M, Benzenine E, Doret M, et al. Continuous anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus: a retrospective cohort on the French National Health Insurance database (EVASION). Am J Gastroenterol. 2018;113:1669\u201377.","journal-title":"Am J Gastroenterol."},{"key":"881_CR73","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jbspin.2015.07.004","volume":"83","author":"F F\u00f6rger","year":"2016","unstructured":"F\u00f6rger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: low drug levels in cord blood but possible risk for maternal infections: a case series of 13 patients. Jt Bone Spine. 2016;83:341\u20133.","journal-title":"Jt Bone Spine."},{"key":"881_CR74","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.40508","volume":"70","author":"MEB Clowse","year":"2018","unstructured":"Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 2018;70:1399\u2013407.","journal-title":"Arthritis Rheumatol."},{"key":"881_CR75","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1136\/gut.2005.078097","volume":"55","author":"U Mahadevan","year":"2006","unstructured":"Mahadevan U. Fertility and pregnancy in the patient with inflammatory bowel disease. Gut. 2006;55:1198\u2013206.","journal-title":"Gut."},{"key":"881_CR76","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s12664-015-0542-y","volume":"34","author":"A Puri","year":"2015","unstructured":"Puri A, Bharadwaj V, Sachdeva S. Extent of disease is a major outcome predictor in patients with ulcerative colitis and pregnancy. Indian J Gastroenterol. 2015;34:108\u201311.","journal-title":"Indian J Gastroenterol."},{"key":"881_CR77","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.3899\/jrheum.140583","volume":"42","author":"B Bharti","year":"2015","unstructured":"Bharti B, Lee SJ, Lindsay SP, et al. Disease severity and pregnancy outcomes in women with rheumatoid arthritis: results from the organization of teratology information specialists autoimmune diseases in pregnancy project. J Rheumatol. 2015;42:1376\u201382.","journal-title":"J Rheumatol."},{"key":"881_CR78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jaad.2010.02.005","volume":"64","author":"YW Yang","year":"2011","unstructured":"Yang YW, Chen CS, Chen YH, et al. Psoriasis and pregnancy outcomes: a nationwide population-based study. J Am Acad Dermatol. 2011;64:71\u20137.","journal-title":"J Am Acad Dermatol."},{"key":"881_CR79","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/2050-6511-14-38","volume":"14","author":"E Brunner","year":"2013","unstructured":"Brunner E, Falk DM, Jones M, et al. Olanzapine in pregnancy and breastfeeding: a review of data from global safety surveillance. BMC Pharmacol Toxicol. 2013;14:38.","journal-title":"BMC Pharmacol Toxicol."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00881-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-019-00881-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-019-00881-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,31]],"date-time":"2020-10-31T00:41:31Z","timestamp":1604104891000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-019-00881-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["881"],"URL":"https:\/\/doi.org\/10.1007\/s40264-019-00881-8","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,1]]},"assertion":[{"value":"1 November 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was supported by Janssen Pharmaceutical Companies of Johnson & Johnson. Janssen was involved in all aspects of the study (design and conduct of the study; collection, management, analysis, and interpretation of data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Anja Geldhof, Jennifer Slater, Michael Clark, Urmila Chandran, and Danielle Coppola are employees of Janssen Research & Development or Janssen Biologics Division and may own company stock\/stock options.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated during and\/or analyzed during the current analysis are not publicly available because access to pharmacovigilance data must always be considered in respect to European Union laws, which protect the patient\u2019s rights to personal privacy. However, upon reasonable request, the data may be made available by contacting the corresponding author.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Sharing"}},{"value":"This observational analysis was based on pregnancy safety data extracted from a global safety database. Clinical trial registration and ethical approval were not required for this analysis. This article also does not contain any data from animals performed by any of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Cumulative pregnancy safety data from a global safety surveillance database were summarized in this observational analysis. No identifying patient information was reported; therefore, no additional informed consent was required.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}}]}}